Efficacy and safety of programmed cell death protein-1 inhibitor for first-line therapy of advanced gastric or gastroesophageal junction cancer: a network meta-analysis
In the first-line treatment of advanced GC/GEJC, PD-1 inhibitors plus chemotherapy have been demonstrated to significantly improve OS, PFS, and ORR compared with chemotherapy. Among them, sintilimab plus chemotherapy achieved the highest SUCRA value for OS, and nivolumab plus chemotherapy achieved the highest SUCRA values for PFS and ORR. Regarding safety, tislelizumab plus chemotherapy and sintilimab plus chemotherapy did not increase the overall incidence of TRAEs and the incidence of grade 3 or worse TRAEs, with good tolerability and safety.
Authors
- Yannan Fan (ORCID: https://orcid.org/0000-0003-3308-6878)
- Wenxing Peng (ORCID: https://orcid.org/0000-0001-7653-4672)
- Yunnan Zhang (ORCID: https://orcid.org/0000-0002-3515-200X)
- Wei Yang (ORCID: https://orcid.org/0000-0003-2945-2898)
- Wenzhou Zhang (ORCID: https://orcid.org/0000-0001-7112-392X)
Institutions
- Capital Medical University (CN)
- Zhengzhou University (CN)
- Beijing Anzhen Hospital (CN)
- Henan Cancer Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-04-08
- DOI
- https://doi.org/10.3389/fimmu.2025.1500954
- Citations
- 3
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 3.14